References
- Comoglu T. Formulation and evaluation of carbamazepine fast disintegrating tablets. Pharm Ind 2010;72:150–158
- Comoglu T, Dogan A, Comoglu S, Basci N. Formulation and evaluation of diclofenac potassium fast disintegrating tablets and their application in migraine patients. Drug Dev Ind Pharm 2011;37:260–267
- Bircan Y, Comoglu T. Formulation technologies of orally fast disintegrating tablets. J Pharm Marmara Univ 2012;16:77–81
- Fu Y, Yang S, Jeong SH, et al. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Ther Drug Carrier Syst 2004;21:433–475
- James K. Solubility and related propeties. Vol. 28. New York: Marcel Dekker; 1986:127–146, 355–395
- Dahima R, Pachori A, Netam S. Formulation and evaluation of mouth dissolving tablet containing amlodipine besylate solid dispersion. Int J ChemTech Res 2010;2:706–715
- The Biopharmaceutics Classification System (BCS) Guidance. Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD; 2001
- Baboota S, Agarwaal SP. Preparation and characterization of meloxicam hydroxy propyl β-cyclodextrin inclusion complex. J Incl Phenom Macrocycl Chem 2005;51:219–224
- Otagiri Imai T, Hirayama F, Uekama K. Improvements to some pharmaceutical properties of flurbiprofen by β and γ cyclodextrin complexations. Acta Pharm Suecica 1983;20:1–10
- Cirri M, Rangoni C, Maestrelli F, et al. Development of fast-dissolving tablets of flurbiprofen--cyclodextrin complexes. Drug Dev Ind Pharm 2005;31:697–707
- Lu Y, Zhang X, Lai J, et al. Physical characterization of meloxicam--β-cyclodextrin inclusion complex pellets prepared by a fluid-bed coating method. Particuology 2009;7:1–8
- Rustichelli C, Gamberini A, Ferioli V, et al. Solid-state study of polymorphic drugs: carbamazepine. J Pharm Biomed Anal 2000;23:41–54
- Bi YX, Sunada Y, Yonezawa Y, Danjo K. Evaluation of rapidly disintegrating tablets prepared by a direct compression method. Drug Dev Ind Pharm 1999;25:571–581
- Sunada H, Bi Y. Preparation, evaluation and optimization of rapidly disintegrating tablets. Powder Technol 2002;122:188–198
- Lai F, Pini E, Angioni G, et al. Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets. Eur J Pharm Biopharm 2011;79:552–558
- El-Mahrouk G, Aboul-Einien MH, Elkasabgy NA. Formulation and evaluation of meloxicam orally dispersible capsules. Asian J Pharm Sci 2009;4:8–22
- Ryan JA. Compressed pellet X-ray diffraction monitoring for optimization of crystallinity in lyophilized solids: imipenem: cilastatin sodiumcase. J Pharm Sci 1986;75:805–807
- Mishra DN, Bindal M, Singh SK, et al. Spray dried excipient base: a novel technique for the formulation of orally disintegrating tablets. Chem Pharm Bull 2006;54:99–102
- Rangasamy M, Balasubramaniam A, Gummadevelly S. Design and evaluation of meloxicam tablet research. J Pharm Tech 2008;1:484–486